Capstone falls on AZX100 data

Capstone Therapeutics (NASDAQ:CAPS) fell $0.52 (50%) to $0.52 on Tuesday after reporting data from three Phase IIa trials of AZX100 in keloid and surgical scarring. The synthetic 24-amino acid peptide analog of heat shock protein 20 (Hsp20) missed the primary endpoint of significantly improving Patient and Observer Scar Assessment Scale scores from baseline to 12 months post surgery vs. placebo in each of the OL-ASCAR-04 and OL-ASCAR-05 trials to reduce or prevent post-excision keloid scarring. ...